详情页

资源类型：

文章类型：

作者：

Zuo, Jing[1] * ; Wang, Ke[2] ; Cui, Zhumei[3] ; Li, Qingshui[4] ; Cheng, Xiaodong[5] ; Zheng, Zhong[6] ; Sun, Lixin[7] ; Zhang, Hui[8]

; Zhang, Jun[8]

; Wang, Shuhe[9] ; Cao, Dongyan[10] ; Chen, Lihong[11] ; Zhao, Hongqin[12] ; Duan, Wei[13] ; Zheng, Min[14] ; Shou, Huafeng[15] ; Li, Jin[6] ; Wang, Yue[16] ; Chen, Xiaoxiang[17] ; Wu, Lingying[1] ;

机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China [2]Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China [3]Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China [4]Shandong Canc Hosp, Jinan, Peoples R China [5]Zhejiang Univ, Womens Hosp, Sch Med, Hangzhou, Peoples R China [6]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China [7]Shanxi Med Univ, Chinese Acad Med Sci, Shanxi Prov Canc Hosp, Shanxi Hosp,Canc Hosp, Taiyuan, Peoples R China [8]Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China [9]Chinese Peoples Liberat Army PLA Gen Hosp, Med Ctr 7, Beijing, Peoples R China [10]Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Beijing, Peoples R China [11]Shaanxi Prov Peoples Hosp, Xian, Peoples R China [12]Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou, Peoples R China [13]Capital Med Univ, Beijing Obstet & Gynecol Hosp, Beijing, Peoples R China [14]Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China [15]Zhejiang Prov Peoples Hosp, Hangzhou, Peoples R China [16]Henan Prov Peoples Hosp, Zhengzhou, Peoples R China [17]Nanjing Med Univ, Jiangsu Canc Hosp, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Nanjing, Peoples R China

出处：

DOI：

ISSN：

语种：

WOS：

中科院分区：

出版当年[2025]版：

大类 | 3 区医学

小类 | 3 区妇产科学 3 区肿瘤学

最新[2025]版：

大类 | 3 区医学

小类 | 3 区妇产科学 3 区肿瘤学

JCR分区：

出版当年[2024]版：

Q1 OBSTETRICS & GYNECOLOGY Q1 ONCOLOGY

最新[2024]版：

Q1 OBSTETRICS & GYNECOLOGY Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

RENI-1: a prospective, multicenter real-world study of niraparib as first-line maintenance therapy in newly diagnosed advanced ovarian cancer

文献详情